Quotient is a commercial-stage diagnostics company. Co. focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. Blood grouping involves specific procedures performed at donor or patient testing laboratories to characterize blood, which includes antigen typing and antibody detection. Disease screening involves the screening of donor blood for unwanted pathogens using two different methods, a serological approach (testing for specific antigens or antibodies) and a molecular approach (testing for DNA or RNA). Co. is developing MosaiQ, its proprietary technology platform and a third microarray for molecular disease screening. The QTNT stock yearly return is shown above.
The yearly return on the QTNT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the QTNT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|